Pittsburgh Post-Gazette

Q&A: Do I need a vaccine booster?

- By Sarah Gantz

With more contagious variants of the COVID-19 virus spreading just as people are starting to feel comfortabl­e re-entering society, talk about the benefit of vaccine boosters is amping up.

Pfizer is seeking approval for a third dose of its vaccine, given as a booster, and some countries, including Britain and Israel, have already said they will boost vulnerable population­s.

Yet the U.S. Centers for Disease Control and Prevention and the Food and Drug Administra­tion have said boosters are not currently necessary for fully vaccinated Americans.

What gives?

We talked to the University of Pennsylvan­ia’s Drew Weissman, an immunologi­st who helped develop the messenger RNA concept behind Pfizer’s vaccine, to unpack the internatio­nal argument over COVID-19 boosters.

What is a booster shot? Vaccines cause our bodies to develop antibodies to protect against a virus. A booster shot is an extra dose that “boosts” immunity by spurring the developmen­t of more antibodies.

There are two types of booster shots: The first kind is a follow-up dose that is identical to the initial vaccine, such as the tetanus booster recommende­d every 10 years. Other vaccine boosters are tweaked from their original form to protect against a new variant. A common example is the influenza vaccine, which is slightly different each season to target the most common current strain of the flu virus.

The type of boosters developed for COVID-19 may vary. A follow-up dose of the original vaccine would have a faster path to regulatory approval, since vaccine makers have already received emergency use authorizat­ion. Tweaked versions of the COVID-19 vaccines could be useful in targeting variants, especially if a variant emerges against which the current vaccines are not effective. No such variant has come about yet — the vaccines have proven effective against the delta and other new variants.

Will booster shots be necessary for the COVID19 vaccine?

Scientists disagree on whether booster shots are necessary. The CDC and FDA have said there is not currently enough research to suggest that boosters are needed because the vaccines are providing good protection from the original strain and variants. Studies have shown the two-dose Pfizer and Moderna vaccines provide greater than 90% protection against infection from the original strain, while the single-shot Johnson& Johnson vaccine provides 66% protection. Nearly all recent COVID-19 hospitaliz­ations and deaths in the United States have been among those who are unvaccinat­ed.

Meanwhile, Pfizer is seeking approval in the United States and Europe for a booster for its COVID19 vaccine after a study in Israel that found the vaccine’s effectiven­ess in preventing infection fell to 64% after six months, though cases of severe illness remained low. Pfizer said that the Israeli findings are consistent with its ongoing Phase 3 clinical trial.

Who is most likely to need a booster?

People who are most vulnerable to severe illness, hospitaliz­ation and death would be top of the list for a booster.

Britain plans to administer boosters to people over age 70 beginning in September and Israel has begun offering a third dose of the Pfizer vaccine to at-risk individual­s.

There is not enough research to know whether boosters are worthwhile for everyone.

Are there other factors that could influence decisions about COVID-19 boosters?

Of course. Government agencies must consider the full scope of the public health emergency when prioritizi­ng resources and strategizi­ng how best to control the pandemic. Should doses go toward boosting the immunity of people who are already vaccinated — and have considerab­le protection against current variants — or toward getting more people their first dose?

Getting as many people vaccinated as possible is the best way to reduce the virus’ spread and minimize the likelihood of a new variant against which the current vaccines are not effective, Dr. Weissman said.

If a new variant arose that escaped current vaccine protection, vaccinatio­n efforts would have to restart with a booster designed to target that variant.

What does the latest Johnson & Johnson risk news mean about vaccine and booster safety?

Through the Vaccine Adverse Event Reporting Systems, a federal monitoring system, officials have identified 100 cases of GuillainBa­rre syndrome among the 12.8 million people who have received the Johnson & Johnson vaccine.

“Every drug we take has adverse events. For the [COVID-19] vaccine, they’re in the one-in-a-million range,” said Dr. Weissman. People are much more likely to die of COVID than they are to develop a complicati­on, he said.

What does it mean if authoritie­s later decide that everyone should get a booster shot? How can we trust those officials?

It means lawmakers are basing their guidance on science, not politics. Science evolves because scientists are constantly learning through new studies. Scientists make recommenda­tions based on what they know right now. But every new study builds on their knowledge of a disease or virus, and as scientists gain a more complete picture of the problem, their guidance may change.

 ?? Post-Gazette ?? Jordyn Schmid, an Indiana University of Pennsylvan­ia student, receives a COVID-19 vaccine from Lauren Mazanowski, a pharmacist with Giant Eagle, in March.
Post-Gazette Jordyn Schmid, an Indiana University of Pennsylvan­ia student, receives a COVID-19 vaccine from Lauren Mazanowski, a pharmacist with Giant Eagle, in March.

Newspapers in English

Newspapers from United States